Monday, 26 Jun 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
15 Feb 2017 Social Correction: Abbvies JAK inhibitor ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese
15 Feb 2017 News Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX https://t.co/7lFqrfL3fF
13 Feb 2017 Social In animal models, abatacept and tofacitinib shown effective in treating suppressing Chikungunya arthritis. https://t.co/LOAinXNOON
10 Feb 2017 News An Integrated Analysis of Tofacitinib Safety
08 Feb 2017 Social Clinical review of anti-GMCSF mAb-mavrilimumab. Preclinical, Phase I/II efficacy & safety in #RA; 60-70% ACR20 resp https://t.co/GyvnSWpo1r
04 Feb 2017 Social Sarilumab (anti-IL-6) "Kevzara" approved by Health Canada for the Rx of RA. Dose 200 mg sc EOW. Let IL6 Wars begin! https://t.co/v3FnfHGUgh
02 Feb 2017 Social Good review and infographic of what #Biosimilars are and whats available. https://t.co/cfsSIgVzPN
02 Feb 2017 News Kevzara (Sarilumab) Approved in Canada for RA
31 Jan 2017 Social @jhoronjeff @pfizer @US_FDA You missed the point - this is the kind of study that must be done to get an interchangeability indication
31 Jan 2017 Social INTERCHANGEABLE: After 1st yr RA pts switch from Remicade to CT-P13 (Inflectra) had same ACR 20/50/70, anti-Drug Abs https://t.co/xoUAX6Qls9
29 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/OlN3Eyqya4
27 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/O2XfkDF6XB
24 Jan 2017 Social FDA has granted priority review designation for use of tocilizumab in giant cell artertitis based on GiACTA study https://t.co/qOeYvZnc9p
23 Jan 2017 Slide of the day Future Biologic Patent Expirations
23 Jan 2017 News FDA Issues Draft Guidance on Biosimilar Interchangeability
16 Jan 2017 Social Baricitinib decision by the FDA extended from Jan 2017 by another 3 mos for FDA to review major amendment to NDA https://t.co/tMi3llwWZw
12 Jan 2017 Social Biosimilar Inflectra priced at only a 15% discount; CMS issues paymentand claims processing information https://t.co/lCwn198PAN
11 Jan 2017 Social The IL-6 Wars By Jack Cush, MD | 10 January 2017 In 1998 the biologic era came in like a lion and has been roaring… https://t.co/0XYpICfif6
10 Jan 2017 Blog The IL-6 Wars